Adorini Luciano, Giarratana Nadia, Penna Giuseppe
BioXell, Via Olgettina 58, Milano I-20132, Italy.
Semin Immunol. 2004 Apr;16(2):127-34. doi: 10.1016/j.smim.2003.12.008.
Immunosuppressive and anti-inflammatory agents are able to generate tolerogenic DCs, leading, in some cases, to induction or enhancement of regulatory T cells with suppressive activity. This novel mechanism of action, shared by several immunosuppressive and anti-inflammatory agents, is becoming firmly established and contributes to explain their functional properties. The possibility to manipulate DCs in vivo using more or less conventional low molecular weight drugs, enabling them to exert tolerogenic activities, could be exploited to better control a variety of chronic inflammatory conditions, from autoimmune diseases to allograft rejection.
免疫抑制和抗炎药物能够产生耐受性树突状细胞(DCs),在某些情况下会导致具有抑制活性的调节性T细胞的诱导或增强。几种免疫抑制和抗炎药物共有的这种新作用机制正在得到确证,并有助于解释它们的功能特性。利用或多或少传统的低分子量药物在体内操纵DCs,使其发挥耐受性活性,这一可能性可用于更好地控制从自身免疫性疾病到同种异体移植排斥等多种慢性炎症性疾病。